Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile

NCT07236697 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-12-01
Last updated
2025-11-19

Condition(s) studied

Subclinical Hypothyroidism

Investigational drug(s) / intervention(s)

liver enzymes

liver enzymes: subclinical hypothyroidism on liver enzymes and lipid profile

Study summary

the goal of the randomized controlled observational study is to observe the effect of subclinical hypothyroidism on liver enzymes and lipid profile

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * • Age ≥ 18 years * For SCH group: Elevated TSH with normal FT4 * For control group: Normal TSH and FT4 levels Exclusion Criteria: * • Evident hypothyroidism or hyperthyroidism * Diagnosed with diabetes mellitus * Chronic liver disease * Chronic kidney disease * Use of lipid-lowering or thyroid medications * Pregnancy * Alcohol abuse

Primary outcome measure(s)

  • Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile — Baseline
    1. Mean levels of liver enzymes (ALT, AST, GGT) • To determine whether there is a statistically significant difference in liver enzyme levels between individuals with subclinical hypothyroidism and euthyroid controls. 2. Mean values of lipid profile components (Total Cholesterol, LDL-C, HDL-C, Triglycerides) • To assess whether subclinical hypothyroidism is associated with dyslipidemia compared to the control group.

Trial sites (1)

FacilityCityRegionStatus
Assiut university hospitals Asyut Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07236697 on ClinicalTrials.gov ↗ ← All trials in Egypt